872 - Voriconazole Therapeutic Drug Monitoring (TDM): How Common is Autoinduction?

Co-Author(s)

• VT

  Varalika Tyagi, n/a

  University of Alberta
  Edmonton, Alberta, Canada

  Disclosure: Disclosure(s): No financial relationships to disclose
• CL

  Cecilia Lau, BScPharm, ACPR

  Pharmacist
  Alberta Health Services
  Edmonton, Alberta, Canada

  Disclosure: Disclosure(s): No financial relationships to disclose
• KD

  Karen Doucette, MD, MSc

  University of Alberta
  Edmonton, Alberta, Canada

  Disclosure: Disclosure(s): No financial relationships to disclose
• CC

  Carlos Cervera, Associate Professor

  Assistant Professor
  University of Alberta
  Edmonton, Alberta, Canada

  Disclosure: Disclosure(s): Astra-Zeneca: Advisor/Consultant (); AVIR Pharma: Grant/Research Support (), Honoraria (); Lilly: Advisor/Consultant (); Merck: Advisor/Consultant (), Grant/Research Support (), Honoraria (); Sunovion: Advisor/Consultant (); Takeda: Advisor/Consultant (), Honoraria (); VerityPharma: Advisor/Consultant ()

Presenting Author(s)

• DK

  Dima Kabbani, MD, MSc (she/her/hers)

  Assistant Professor
  University of Alberta
  Edmonton, AB, Canada

  Disclosure: Disclosure(s): AVIR Pharma: Grant/Research Support (), Honoraria (); GSK: Honoraria (); Merck: Grant/Research Support ()